Defining the metabolic limitations of tumour growth will help to develop cancer therapies 1 . Cancer cells proliferate slower in tumours than in standard culture conditions, indicating that a metabolic limitation may restrict cell proliferation in vivo. Aspartate synthesis can limit cancer cell proliferation when respiration is impaired 2-4 ; however, whether acquiring aspartate is endogenously limiting for tumour growth is unknown. We confirm that aspartate has poor cell permeability, which prevents environmental acquisition, whereas the related amino acid asparagine is available to cells in tumours, but cancer cells lack asparaginase activity to convert asparagine to aspartate. Heterologous expression of guinea pig asparaginase 1 (gpASNase1), an enzyme that produces aspartate from asparagine 5 , confers the ability to use asparagine to supply intracellular aspartate to cancer cells in vivo. Tumours expressing gpASNase1 grow at a faster rate, indicating that aspartate acquisition is an endogenous metabolic limitation for the growth of some tumours. Tumours expressing gpASNase1 are also refractory to the growth suppressive effects of metformin, suggesting that metformin inhibits tumour growth by depleting aspartate. These findings suggest that therapeutic aspartate suppression could be effective to treat cancer.
asparaginase activity, the enzymatic activity that converts asparagine to aspartate, such an activity is found in some organisms 15 . We reasoned that because the level of asparagine is more abundant in the circulation, providing cancer cells with an asparaginase activity may be a method to provide aspartate to the cells in tumours.
Human cells have two genes that encode products with homology to asparaginase enzymes from other organisms, but these gene products have not shown robust asparaginase activity 5, 16 and alternative enzymatic functions have been proposed 16, 17 . However, it has been hypothesized that asparaginase activity might be activated in some contexts 18 . Thus, we first examined whether asparagine could functionally contribute to the aspartate pool in cells. Providing U- 13 C-labelled asparagine to cells contributed to the intracellular asparagine pool when supplied in the micromolar range; however, U-13 C-labelled aspartate only labelled the intracellular aspartate pool when provided at millimolar concentrations ( Fig. 1a ). Overexpression of the glial transporter solute carrier family 1 member 3 (SLC1A3), which can transport aspartate 4, 19 , allows labelling of intracellular aspartate from micromolar levels of labelled extracellular aspartate, confirming that aspartate is relatively impermeable to cells without this transporter ( Supplementary Fig. 1a ). To confirm that these labelling differences reflect intracellular amino acid pools, we examined the incorporation of labelled aspartate or asparagine into protein over 24 hours and found that the label from asparagine incorporated into protein at lower extracellular concentrations than the label from aspartate (Fig. 1b ). Exogenous asparagine also increased intracellular asparagine levels when provided at micromolar levels, whereas the addition of 10 mM aspartate was needed to even slightly increase aspartate levels in cells ( Fig. 1c,d) . The expression of SLC1A3 enabled exogenous aspartate to raise intracellular pools at lower aspartate concentrations, which is consistent with aspartate being relatively impermeable to non-SLC1A3-expressing cells ( Supplementary Fig. 1b ). In fact, extracellular aspartate only marginally contributes to intracellular aspartate levels, whereas extracellular asparagine contributes considerably to intracellular asparagine levels, across several cancer cell lines cultured in the presence of 1 mM U-13 C-labelled aspartate or asparagine ( Supplementary Fig. 1c-f ). Taken together, these data are consistent with previous studies [20] [21] [22] suggesting that many cancer cells can take up asparagine, but not aspartate.
Although these data indicate a difference in the ability of physiological levels of aspartate and asparagine to enter cells, we also determined whether these permeability characteristics applied to their Letters NATure Cell Biology release from cells. To test this, we measured the extracellular release of metabolites into saline with and without the detergent saponin ( Fig. 1e ). Saponin can form pores when complexed to cholesterol in the cell membrane, a process that takes approximately 5 minutes, causing the release of cytosolic small molecules by diffusion 3 . We reasoned that permeable metabolites would equilibrate rapidly asparagine, but not aspartate, is accessible to cells. a, Fractional labelling of intracellular asparagine and aspartate in 143B cells after 1 hour of exposure to the indicated concentrations of U-13 C-labelled asparagine or U-13 C-labelled aspartate. b, Fractional labelling of total asparagine plus aspartate in protein hydrolysates derived from 143B cells cultured for 24 hours with the indicated concentrations of U-13 C-labelled asparagine or U-13 C-labelled aspartate. Acid hydrolysis of protein cleaves amides to carboxylic acids and converts all asparagine to aspartate. Thus, the labelled aspartate measured represents the sum of the labelled aspartate and asparagine in protein in these cells. c, Intracellular asparagine levels from 143B cells cultured in the indicated concentrations of asparagine for 1 hour. d, Intracellular aspartate levels from 143B cells cultured in the indicated concentrations of aspartate for 1 hour. e, A schematic detailing the saponin-specific metabolite release assay used in panel f and Supplementary Fig. 1g . f, The saponin-specific metabolite release of asparagine and aspartate. g, Fractional labelling of intracellular aspartate from the indicated cancer cell lines cultured with 1 mM U-13 C-labelled asparagine (ASN) for 24 hours. h, A schematic summarizing the permeability of asparagine and aspartate (ASP) and the inability of cells to convert asparagine to aspartate. The P values were calculated by unpaired, one-tailed t-test (c,d,f). The values denote the mean ± s.e.m. Sample size (n) = 3 independent biological replicates from a single representative experiment (a-d,f,g). The source data for f and g are available in Supplementary Table 1 .
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with extracellular saline, whereas impermeable metabolites would only equilibrate after the cytoplasmic membrane was permeabilized with saponin. Lactate, a molecule known to rapidly equilibrate across cell membranes, showed no difference in concentration in extracellular saline with or without saponin, whereas glutamate, a molecule known to be concentrated in cells and not readily exported without co-import of another amino acid 23 , showed saponinspecific metabolite release ( Supplementary Fig. 1g ). Aspartate, but not asparagine, also shows saponin-specific metabolite release, further arguing that, unlike asparagine, aspartate is not readily transported across cell membranes ( Fig. 1f ). Despite the ability to take up asparagine, none of the cancer cells tested displayed robust conversion of 13 C-asparagine to 13 C-aspartate ( Fig. 1g ). These data confirm that asparagine, but not aspartate, is permeable to cell membranes at physiological concentrations and that these cancer cells lack the ability to convert asparagine to aspartate ( Fig. 1h ).
We hypothesized that if cells were able to convert asparagine to aspartate, extracellular asparagine might be able to contribute to intracellular aspartate levels ( Fig. 2a ). Guinea pigs are relatively unique among mammals in possessing asparaginase activity in their blood 24 . The protein responsible for this activity, guinea pig asparaginase 1 (gpASNase1), has only recently been identified 5 . We confirmed that recombinant gpASNase1 has asparaginase activity ( Supplementary Fig. 2a ). When epitope-tagged gpASNase1 is expressed in 143B cells ( Fig. 2b) , an increase in cellular asparaginase activity is observed ( Supplementary Fig. 2b ). The expression of gpASNase1 results in a minor proliferation defect compared to empty vector (ev) control cells in media lacking asparagine and has no effect on proliferation in media with asparagine ( Fig. 2c ). As asparagine depletion can lead to cell death in certain contexts [20] [21] [22] , we determined whether gpASNase1 expression could negatively affect cells when asparagine synthesis was impaired. Indeed, short hairpin RNA (shRNA)-mediated knockdown of asparagine synthetase (ASNS) does not affect cell viability when asparagine is available, but synergizes with gpASNase1 to kill cells cultured without asparagine ( Supplementary Fig. 2c-e ). These data confirm that asparagine depletion can impair viability and argue that these cells have sufficient endogenous ASNS capacity to avoid detrimental effects of asparagine consumption by gpASNase1.
To determine whether gpASNase1 expression changes nutrient utilization, we examined asparagine levels in the media over time for gpASNase1-expressing and control cells. Whereas control cells net produce asparagine, gpASNase1 cells consume asparagine ( Fig. 2d ). When cells are cultured in media containing U-13 C-labelled asparagine, gpASNase1-expressing cells exhibit increased aspartate levels, with a substantial fraction of the aspartate labelled from U-13 C asparagine ( Fig. 2e ). Asparagine-derived aspartate is also incorporated into known aspartate-utilizing pathways, including the tricarboxylic acid (TCA) cycle and pyrimidine synthesis ( Supplementary Fig. 2f ,g). Cells expressing gpASNase1 had increased levels of some aspartate-derived metabolites compared to control cells ( Supplementary Fig. 2h ), but consistent with previous work [2] [3] [4] , aspartate supplementation did not affect the intracellular NAD + /NADH ratio ( Supplementary Fig. 2i ). These data indicate that gpASNase1 expression confers the ability to convert environmental asparagine into intracellular aspartate and downstream products of aspartate metabolism.
The expression of gpASNase1 is predicted to restore proliferation to aspartate-limited cells when asparagine is available. As glutamine is a major source of intracellular aspartate for most cells in culture [25] [26] [27] , we examined whether gpASNase1 provides an orthogonal source of aspartate and decreases glutamine utilization ( Fig. 3a) . Indeed, providing asparagine decreased anaplerotic glutamine consumption (glutamine consumed − glutamate released) in gpAS-Nase1-expressing cells, but in not control cells, and had no effect on other major nutrient fluxes ( Fig. 3b and Supplementary Fig. 3a,b ).
Asparagine also restores the proliferation of gpASNase1-expressing cells, but not control cells, in glutamine-limited conditions ( Fig. 3c ).
Inhibiting mitochondrial respiration decreases aspartate synthesis, making cells dependent on alternative electron acceptors or supplementation with supraphysiological concentrations of aspartate [2] [3] [4] 10, 28, 29 (Fig. 3d ). We confirmed that rotenone, an inhibitor of mitochondrial electron transport chain complex I, inhibits the proliferation of control and gpASNase1 cells in the absence of asparagine and that supplementation with 20 mM aspartate restores proliferation ( Fig. 3e ). Asparagine supplementation restores gpASNase1-expressing cell proliferation, but not control cell proliferation, to rotenone-treated cells, consistent with gpASNase1 expression allowing asparagine to support aspartate levels ( Fig. 3e ). Supplementation with nucleotide precursors that bypass the demand for aspartate to support nucleotide synthesis can also partially restore rotenone-treated cell proliferation 
Fig. 2 | Heterologous expression of gpASNase1 confers asparaginase activity to cells. a, A schematic depicting how the intracellular expression
of gpASNase1 allows environmental asparagine to support intracellular aspartate levels. b, Western blot analysis of 143B cells expressing empty vector (ev) or FLAG-tagged gpASNase1 as indicated. gpASNase1 expression is detected with an anti-FLAG antibody, and vinculin expression is also shown as a loading control. The predicted molecular weight of gpASNase1 is 60 kDa. This experiment was repeated four times with similar results. c, The relative cell number over time of 143B cells expressing ev or gpASNase1, in the presence or absence of 1 mM asparagine as indicated (left). These data were used to calculate the proliferation rate (right). d, Asparagine production/consumption rate of 143B cells expressing ev or gpASNase1 cultured in 1 mM asparagine as indicated. The P value was calculated by unpaired, one-tailed t-test. e, Measurement of aspartate levels (the magnitude of the bars) and fractional isotopomer labelling (coloured segments) of ev or gpASNase1expressing 143B cells cultured with 1 mM U-13 C-labelled asparagine for 24 hours. The values denote the mean ± s.e.m. Sample size (n) = 3 independent biological replicates from a single representative experiment (c-e). The source data for c and e are available in Supplementary Table 1 .
( Supplementary Fig. 3c ). These data highlight the demand for aspartate to support nucleotide synthesis, but do not exclude protein synthesis as another process that is in critical demand for aspartate. Two respiration-incompetent cell lines, 143B cytB and UOK262 cells, require exogenous electron acceptors or high-dose aspartate treatment to proliferate 2,4,28 , and asparagine only restored the proliferation of these cells when gpASNase1 was expressed ( Supplementary Fig. 3d,e ). The expression of gpASNase1 also partially restored cell proliferation in hypoxia (0.8% O 2 ), an electron-acceptor-deficient state experienced by cancer cells in vivo, but only when asparagine was provided in the culture media ( Fig.  3f ). In fact, 143B-derived xenograft tumours show comparable levels of hypoxia-inducible factor 1-α (HIF1-α ) protein, a marker of hypoxia, as 143B cells cultured in 0.8% O 2 ( Supplementary Fig. 3f ). These data support the hypothesis that environmental conditions in vivo may cause aspartate acquisition to be a metabolic limitation for tumour growth.
To determine whether expressing gpASNase1 allows cancer cells to obtain aspartate from circulating asparagine, we quantified aspartate and asparagine levels in mouse plasma and found micromolar concentrations of each, which is consistent with previous reports 14 (Fig. 4a ). At these concentrations, asparagine is permeable to cells, whereas aspartate is not ( Fig. 1a ). We then measured the contribution of U-13 C-labelled asparagine to intracellular aspartate in control and gpASNase1 cells at physiological asparagine concentrations. Under these conditions, asparagine labelled the intracellular aspartate pool in gpASNase1-expressing cells, with approximately 20% of the intracellular aspartate pool being derived from asparagine after 3 hours and reaching steady state at approximately 25% labelling after 8 hours ( Fig. 4b and Supplementary  Fig. 4a ). In addition, physiological asparagine levels can partially restore the proliferation of gpASNase1-expressing cells that are subjected to rotenone treatment or glutamine limitation ( Fig. 4c and Supplementary Fig. 4b ).
We next determined whether gpASNase1 expression could change aspartate metabolism in tumours and affect tumour growth in vivo. Implantation of control and gpASNase1-expressing 143B cells into nu/nu mice resulted in differential tumour growth, with gpASNase1-expressing tumours growing faster than tumours derived from control cells ( Fig. 4d ), resulting in larger tumour volumes 13 days post-tumour implantation (Fig. 4e,f) . The expression of gpASNase1 did not affect the efficiency of tumour initiation, arguing that this size difference reflects faster tumour growth ( Supplementary Fig. 4c ). A similar increase in tumour growth rate in gpASNase1-expressing cells is observed when implanted with control cells into opposite flanks on the same mouse, indicating that gpASNase1 expression does not increase tumour growth via a systemic effect ( Supplementary Fig. 4d ). Measurement of intratumoural metabolites shows an increased aspartate/asparagine ratio in gpASNase1-expressing tumours, consistent with increased 
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NATure Cell Biology asparagine to aspartate conversion ( Fig. 4g ). To directly test asparaginase activity in tumours, we injected U-13 C asparagine or vehicle into mice harbouring tumours with or without gpASNase1 expression. Consistent with the intracellular metabolism of U-13 C asparagine, we only observed robust malate labelling in gpASNase1expressing tumours (Fig. 4h ). We tested whether gpASNase1 expression affects the growth of tumours derived from cancer cells of different tissue origins and genotypes. We expressed gpASNase1 and observed conversion of asparagine to aspartate in gpASNase1-expressing HCT116, AL1376
and AsPC-1 cells ( Supplementary Fig. 4e ,f). The expression of gpAS-Nase1 increased tumour growth in HCT116-derived and AL1376derived tumours, but not in AsPC-1-derived tumours, suggesting that some cancer cells are aspartate limited in tumours but that aspartate is not limiting the growth of all tumours ( Supplementary  Fig. 4g ). In all cases, increases in the intratumoural aspartate/ asparagine ratio were observed in gpASNase1 tumours and there were no significant differences in the rate of tumour formation ( Supplementary Fig. 4h ,i). The expression of gpASNase1 altered several metabolite levels in tumours, although the most consistent This experiment was repeated once with similar results. c, The proliferation rate of 143B cells expressing ev or gpASNase1, with or without rotenone (120 nM), and cultured in media with the indicated concentrations of asparagine. d, The volumes of tumours derived from 143B cells expressing ev or gpASNase1 measured over time as indicated. e, Tumour volumes 13 days after implantation of 143B cells expressing ev or gpASNase1 as indicated. f, Tumours dissected 13 days after implantation of 143B cells expressing ev and gpASNase1 from a separate experiment than (d and e). g, The relative aspartate/asparagine ratio from tumours derived from 143B cells expressing ev or gpASNase1 as indicated. h, The measurement of labelled M+ 4 malate in tumours derived from AL1376 cells expressing ev or gpASNase1 following two boluses of either vehicle (saline) or 30 mg ml −1 U-13 C asparagine. i, Assessment of tumour volume over time for tumours derived from 143B cells expressing ev or gpASNase1 in mice that were treated with either vehicle (water) or 1 g per kg metformin once daily by oral gavage. Treatment was initiated in mice with size-matched tumours after reaching 45 mm 3 . The P values were calculated by unpaired, one-tailed t-test (c-e,g-i). The values denote the mean ± s.e.m. Sample size (n) = 7 independent biological replicates from a single representative experiment (a); n = 3 independent biological replicates from a single representative experiment (b,c); 10 mice were injected per genotype, with 3 injections per mouse (d-f), yielding n = 27 (ev) and n = 28 (gpASNase1); n = 5 measurements from independent tumours from each genotype (g); n = 6 (vehicle) or n = 9 (bolus) independent tumour samples from each genotype (h). For i, 5 mice were used per group harbouring 3 injection sites each; when tumours reached ≥ 45 mm 3 , they were put on study, occasionally resulting in multiple tumours per mouse going on study, yielding n = 6 (ev vehicle and ev metformin), n = 7 (gpASNase1 vehicle) and n = 8 (gpASNase1 metformin). The source data for b, d and i are available in Supplementary Table 1 .
NATure Cell Biology change was decreased asparagine levels ( Supplementary Fig. 4j ). As observed in culture, gpASNase1 expression did not alter NAD + levels in tumours ( Supplementary Fig 4k) . Collectively, these data indicate that gpASNase1 expression can supply aspartate in physiological contexts and that obtaining aspartate can limit the growth of some tumours. The expression of asparaginases from other organisms can have differential effects on tumour growth 22 , potentially indicating that the mammalian asparaginase used here has enzyme properties that preclude intracellular asparagine depletion to deleterious levels. Regardless, the observation that SLC1A3 expression can also increase tumour growth supports aspartate production being limiting in some cancers 19 . Different tumours rely on distinct metabolic pathways to support growth, which can be influenced by the cancer genotype, tissue environment and cell lineage 1 . The finding that cancer cells of disparate lineage and genotype can be engineered to grow tumours faster by expressing gpASNase1 suggests that acquiring aspartate may be a metabolic limitation for a subset of cancers. Different pathways can support aspartate levels in tumours from different tissues. For example, glucose supports aspartate synthesis in some lung cancers 7, 9 , whereas some pancreatic cancers catabolize extracellular protein as a source of aspartate 30 . Importantly, inhibition of these pathways in their respective contexts can suppress tumour growth in vivo 7, 9, 31 . Another potential method to suppress aspartate levels in tumours is to inhibit mitochondrial respiration. Indeed, the anti-diabetes drug metformin can inhibit tumour growth via cancer cell-autonomous inhibition of mitochondrial complex I 12, 32 . The anti-cancer activity of metformin can correspond with decreases in intratumoural aspartate levels, suggesting that metformin may suppress tumour growth through aspartate limitation 3 . To test this, we implanted 143B cells with or without gpASNase1 expression into nu/nu mice and, upon tumours reaching 45 mm 3 , treated the mice with either metformin or vehicle. Whereas metformin suppressed the growth of control tumours, metformin had no effect on the growth of gpASNase1expressing tumours (Fig. 4i) . These data support the hypothesis that metformin can suppress tumour growth by exacerbating an endogenous aspartate limitation.
Why some cancer cells are more aspartate limited than others is unknown, but may be related to the method by which they acquire aspartate or their metabolic gene expression 33 . One possible contributor is intratumoural hypoxia, which limits access to the electron acceptors that are important for aspartate synthesis. The finding that gpASNase1 has no effect on AsPC-1 tumour growth argues that aspartate is not necessarily a limiting metabolite for the growth of all tumours or, by extension, all proliferating cells in normal tissues. Thus, these data argue that targeting aspartate production may have particular efficacy to inhibit the growth of some tumours.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41556-018-0125-0.
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Methods Cell culture and the generation of cell lines. All cell lines were passaged in DMEM with pyruvate (50-003, Corning) supplemented with 10% FBS (Sigma) and penicillin-streptomycin (Corning). The identity of 143B, 468, 786-o, A172, AsPC-1, HCT116, HeLa, HT1080 and TT cells were authenticated by satellite tandem repeat testing and referenced to the American Type Culture Collection (ATCC) values. AL1376 cells were generated in-house from a pancreatic tumour from the KP-/-C (Kras G12D/+ ; Trp53 fl/fl ; Pdx1-cre) mouse model of pancreatic adenocarcinoma. All cell lines were negative for mycoplasma (MycoAlert, Lonza). For experiments, media were changed to DMEM without pyruvate (50-013, Corning) supplemented with 10% dialysed FBS (Sigma), penicillin-streptomycin and treatments as indicated. 143B CytB cells were also supplemented with 0.1 mg ml −1 uridine.
The protein sequence of gpASNase1 was reverse translated into a nucleotide sequence, which was synthesized and inserted into a pUC57 plasmid (Biomatik). Primers were designed to amplify the gpASNase1 sequence, encode a carboxy-terminal FLAG tag and use restriction cloning to insert gpASNase1 into the plasmid pLHCX. The primers used were: AAATTTAAGCTTATGGCCCGAGCGAGTGGTAG a nd C CA GAGGTGCCACCT GCCATTGGTTCTGGTTCTGACTACAAAGACGATGACGACAAGTAGATCGAT AAATTT, both 5′ to 3′ . HindIII and ClaI were used to cut at the restriction sites.
A retrovirus was generated in HEK293T cells by transfection using standard techniques. Cells were infected with virus containing either ev pLHCX or gpASNase1 pLHCX and were selected with 200 μ g ml −1 (143B, 143B CytB, UOK262 and AsPC-1) or 500 μ g ml −1 (AL1376 and HCT116) hygromycin B (Invitrogen). Cells were maintained in hygromycin B-containing media until all uninfected control cells had died.
The expression of SLC1A3 was accomplished in 143B cells using virus generated from PMXS-SLC1A3, a gift from D. Sabatini (Addgene plasmid 72873). Standard techniques were used and cells were selected in 5 μ g ml −1 blasticidin (Invitrogen).
Knockdown of ASNS was accomplished in 143B cells using standard techniques to generate virus containing pLKO.1 shRNA targeting either human ASNS (TRCN0000290103 (ASNS1) and TRCN0000290105 (ASNS2), Sigma) or GFP (Addgene plasmid 30323). Cells were maintained in 2 μ g ml −1 puromycin containing media until all uninfected control cells had died.
Metabolite permeability assays. Cells were plated in 6-well dishes at 2.5 × 10 5 cells per well and allowed to incubate overnight. The next day, cells were washed two times with PBS, 4 ml media containing the indicated concentrations of U-13 Clabelled aspartate and asparagine was added and cells were incubated for 1 h. At the end point, cells were washed three times with ice-cold saline and extracted with 300 μ l 80% methanol containing norvaline standard. Extracts were centrifuged at 21,000g for 10 min at 4 °C, 200 μ l supernatant was moved to a fresh microcentrifuge tube and extracts were dried under N 2 gas. Dried extracts were then frozen at -80 °C before subsequent derivatization and measurement by gas chromatography mass spectrometry (GCMS; aspartate) or resuspension in 1:1 acetonitrile:H2O and measurement by liquid chromatography mass spectrometry (LCMS; asparagine).
GCMS.
Polar metabolites were analysed by GCMS. Dried extracts were derivatized with 16 μ l methoxamine (MOX) reagent (Thermo Scientific) for 60 min at 37 °C followed by 20 μ l N-tert-butyldimethylsilyl-N-methyltrifluoroacetamide with 1% tert-butyldimethylchlorosilane (Sigma) for 30 min at 60 °C. Following derivatization, samples were analysed using an Agilent 7890A gas chromatograph using a DB-35MS column (Agilent) coupled to an Agilent 5975C mass spectrometer. Mass isotopomer distributions and total ion counts were determined by integrating metabolite ion fragments and were corrected for natural abundance.
LCMS. LCMS analyses were conducted on a QExactive benchtop orbitrap mass spectrometer equipped with an Ion Max source and a HESI II probe, coupled to a Dionex UltiMate 3000 UPLC system (Thermo Fisher Scientific). External mass calibration was performed using the standard calibration mixture every 7 days. Of each sample, 1-2 µ l was injected onto a SeQuant ZIC-pHILIC 2.1 × 150 mm (5-µ m particle size) column (EMD Millipore) using chromatographic separation conditions and mass spectrometry operating conditions previously described 2 . Metabolites were monitored in full-scan, polarity-switch mode with a range of 70-1,000 m/z. The relative quantitation of polar metabolites was performed with XCalibur QuanBrowser 2.2 (Thermo Fisher Scientific) using a 5 ppm (parts per million) mass tolerance and referencing an in-house library of chemical standards. For the stable isotope labelling studies, data were corrected for natural abundance.
Protein hydrolysis. 143B cells were plated into 6-well dishes at 1.5 × 10 5 cells per well and allowed to incubate overnight. The next day, cells were washed two times with PBS, 4 ml media containing the indicated concentrations of U-13 C-labelled aspartate and asparagine was added and cells were incubated for 24 h. At the end point, cells were washed with PBS, trypsinized, washed with PBS two more times and pelleted. Acid hydrolysis of cellular proteins was performed on cell pellets by boiling in 1 ml of 6 M HCl for amino acid analysis (Sigma) overnight at 100 °C. The HCl solution (50 μ l) was then dried under nitrogen while heating at 80 °C. The dried hydrolysates were then frozen at -80 °C before subsequent derivatization and measurement by GCMS.
Saponin-specific metabolite release. 143B cells (1 × 10 6 ) were split onto a 6-well dish and incubated overnight. The next day, the media were quickly decanted and 1 ml saline with or without 100 μ g ml −1 saponin was added to cells. After 0.5, 2, 10 and 30 min, 50 μ l was removed to a microcentrifuge tube and set on ice. Of each sample, 20 μ l was added to 300 μ l HPLC grade ethanol. Samples were centrifuged at 21,000g for 10 min at 4 °C, 200 μ l supernatant was moved to a fresh microcentrifuge tube and extracts were dried under N 2 gas. Samples were resuspended in 20 μ l 1:1 H 2 O:acetonitrile, and metabolites were measured by LCMS. Owing to differences in metabolite transport, ionization efficiencies of different molecules and different residual concentrations from the original media, the magnitude that a molecule changes over time cannot be used to interpret its relative concentration in cells or media. However, a change in the metabolite levels after saponin pore formation relative to untreated saline indicates that the metabolite is not released from cells in saline as readily as when cells were permeabilized. Cellular asparaginase activity. Cells were plated into 6-well dishes at 1.5 × 10 5 cells per well and allowed to incubate overnight. The next day, cells were washed two times with PBS, 4 ml media containing 1 mM U-13 C-labelled asparagine was added and cells were incubated for the indicated time. At the end point, cells were washed three times with ice-cold saline and extracted with 300 μ l 80% methanol containing norvaline standard. Extracts were centrifuged at 21,000g for 10 min at 4 °C, 200 μ l supernatant was moved to a fresh microcentrifuge tube and extracts were dried under N 2 gas. Dried extracts were then frozen at -80 °C before subsequent derivatization and measurement of aspartate isotopomer abundance by GCMS.
Purification of recombinant asparaginase. gpASNase1 was cloned into pET28a + by Gibson Assembly (New England Biolabs) according to the manufacturer's protocol. The resulting vector encodes gpASNase1 with a C-terminal 6xHis tag following a Ser-Gly-Ser-Gly linker. The vector was transformed into BL21(DE3) Escherichia coli, which were grown at 37 °C to an optical density of 0.7 at 600 nm before asparaginase expression was induced with 0.5 mM (final) isopropyl-β -d-1-thiogalactopyranoside for 6 h at room temperature. Bacteria were flash frozen, resuspended in lysis buffer (50 mM Tris-HCl (pH 8.5), 300 mM NaCl, 10% (v/v) glycerol and 5 mM imidazole) and lysed by sonication. The clarified lysate was incubated with Ni-NTA agarose beads (Qiagen), and the bound material was washed extensively with wash buffer (lysis buffer containing 30 mM imidazole) before elution into elution buffer (50 mM Tris-HCl (pH 8.5), 250 mM NaCl, 10% (v/v) glycerol and 250 mM imidazole). The eluted enzyme was dialysed against dialysis buffer (50 mM Tris-HCl (pH 7.5), 25 mM NaCl and 20% (v/v) glycerol) overnight before being aliquoted and frozen.
Recombinant asparaginase activity. Asparaginase catalytic activity was monitored by a linked assay described previously 5 . In this assay, aspartate produced by the hydrolysis of asparagine is transaminated to oxaloacetate that is reduced to malate, resulting in the loss of NADH, and the rate of consumption of NADH is calculated from the decrease in absorbance at 340 nm. Each reaction included 200 µ M NADH, 200 µ M α -ketoglutarate, 5 U glutamate-oxaloacetate transaminase (Roche) and 1.5 U malate dehydrogenase (Roche), as well as reaction buffer (100 mM Tris-HCl (pH 7.5) and 100 mM KCl). Reactions were conducted in a 100-µ l volume at room temperature. Each reaction contained either commercial E. coli asparaginase (Biovendor), recombinant His-tagged gpASNase1 at the indicated final concentrations, hypotonic lysate (at 600 µ g ml −1 final concentration) or buffer (no enzyme control). Activity was determined in the presence or absence of 1 mM asparagine. To control for the non-specific loss of NADH absorbance, each specific activity value reported is the difference between these values. Hypotonic lysates were prepared by washing trypsinized cells with cold PBS before incubation in hypotonic buffer (20 mM HEPES-KOH (pH 7.0), 5 mM KCl, 1 mM MgCl 2 , 0.5 mM dithiothreitol and 1× cOmplete mini protease inhibitor (Roche)) for 10 min on ice. Cells were lysed by passing them through a 22.5-gauge needle 15 times, and lysates were clarified for 10 min at 4 °C. KCl was added to a final concentration of 100 mM. Protein concentrations were determined by Bradford assay using BSA as a standard.
Proliferation assays. Cells were plated in replicate in 6-well dishes (Corning), with an initial seeding density of 20,000 cells per well for 143B cells and 30,000 cells per well for 143B CytB and UOK262 cells. After seeding, cells were allowed to equilibrate overnight and one six-well dish was counted to quantify the starting cell number prior to treatment. The wells in the remaining dishes were washed twice with PBS and 4 ml of media containing the indicated treatments was added. Final cell counts were determined 4 days after the initial treatment using a Cellometer Auto T4 Plus Cell Counter (Nexcelom Biosciences). The proliferation rate was determined based on the following formula: Letters NATure Cell Biology determined by BCA Protein Assay (Pierce) using BSA as a standard. Samples were resolved by SDS-PAGE using standard techniques, and protein was detected with the following antibodies: primary antibodies: FLAG (1:1,000; 2368, Cell Signaling), vinculin (1:10,000; ab18058, Abcam), ASNS (1:250; HPA029318, Sigma) and HIF1-α (1:250; 610958, BD Transduction Laboratories); secondary antibodies: IR680LT dye-conjugated anti-rabbit IgG (1:10,000; 925-68021, Licor Biosciences), IR800 dye-conjugated anti-mouse IgG (1:10,000; 925-32210, Licor Biosciences) and horseradish peroxidase-linked anti-mouse IgG (1:10,000; 7076S, Cell Signaling). FLAG and ASNS blots were imaged by an Odyssey infrared scanner (Licor Biosciences) and analysed using Image Studio Lite. HIF1-α blots were imaged with film (Denville Scientific).
Metabolite consumption or production. Metabolite consumption or production was determined by measuring the change in the metabolite levels in the medium collected from the culture of proliferating cells. The cell numbers were measured from duplicate treatment plates to determine the proliferation rate, and the metabolite flux was determined with the following formula: Asparagine levels in the medium were quantified by LCMS and compared to a standard curve of U-13 C asparagine in the medium. Measurements of glucose, lactate, glutamine and glutamate in the medium were measured on a YSI-2950 Biochemistry Analyzer (Yellow Springs Instruments).
Mouse studies.
All experiments performed in this study were approved and compliant with ethical regulations regarding animal research provided by the MIT Committee on Animal care (IACUC). Nu/nu mice were purchased from Charles River (088) with ad libitum access to food and water.
Mouse plasma metabolite measurement. To collect mouse plasma samples, animals were anaesthetized using a mixture of isofluorane and oxygen and blood was collected into EDTA-containing tubes via retro-orbital bleeding. Samples were centrifuged at 3,000 r.p.m. for 10 min at 4 °C, and the supernatant was collected and re-centrifuged. Plasma samples were collected and stored at − 80 °C until further analysis.
Xenograft tumour growth. Cancer cells were suspended in 100 μ l PBS and injected into the flanks of 6-8-week-old, male nu/nu mice at 1 × 10 6 cells per injection (143B and AsPC-1), 2 × 10 5 cells per injection (AL1376) or 3 × 10 6 cells per injection (HCT116). When tumours became palpable, the tumour volume was measured by calipers in two dimensions and the volumes were estimated using the equation V = (π /6)(L x W 2 ). Only tumour sites that formed tumours by the end point of the growth assay were measured and factored into the tumour volume calculation. For experiments comparing ev and gpASNase1-expressing cells, sample size estimates were not conducted prior to initiating the experiments, mice were not randomized and the primary investigator was not blinded during or after the experiment, although results were qualitatively verified by blinded investigators. For experiments determining the efficacy of metformin treatment in tumours derived from cells expressing ev or gpASNase1, tumours were permitted to grow to 45 mm 3 , after which animals were randomly assigned to the treatment or the vehicle group. Vehicle (water) or 1 g per kg metformin (in water) was dosed via oral gavage daily for 8 days. Measurements of tumour volume for this experiment were conducted by a blinded investigator. Mice were killed at end points that were consistent with our mouse protocol or before if recommended by the veterinary staff.
Tumour metabolite extraction. After excision, tumours were rapidly freeze clamped using a liquid-nitrogen-cooled BioSqueezer (Biospec Products) and stored at − 80 °C. Pieces of frozen tumour tissue (5-20 mg) were cryogenically homogenized (Retsch Cryomill) and extracted with 1.3 ml 6:3:4 methanol:H 2 O:chloroform. Tumour extractions were vortexed at 4 °C for 10 min, centrifuged at 21,000g for 10 min at 4 °C, and 500 μ l of the upper, aqueous layer was moved to a fresh microcentrifuge tube and dried under N 2 . Dried extracts were resuspended in 50 μ l acetonitrile:H 2 O and metabolites were measured by LCMS.
Tumour protein extraction. Pieces of frozen tumour tissue (5-20 mg) were homogenized in 300 μ l of ice-cold RIPA buffer containing cOmplete Mini protease inhibitors (Roche) and 1% Antifoam Y-30 (Sigma) using gentleMACS dissociators (Miltenya Biotec). Tissue homogenate protein was quantified and analysed as normal for western blot analysis.
Asparagine tracing in tumours. Following xenograft growth assay of AL1376 cells expressing ev or gpASNase1, mice were given a retro-orbital bolus of either vehicle (saline) or 30 mg ml −1 U-13 C asparagine at time 0 and 30 min. One hour after the initial bolus, mice were killed and tumours were extracted for metabolite analysis by LCMS, as detailed above. Owing to small contaminating amounts of U-13 C aspartate in the U-13 C asparagine stock, the measurement of M+ 4 aspartate in tumours was confounded by labelled aspartate in the blood. As this blood level of aspartate was far below what is required to enter cells, we rationalized that we could use a downstream metabolite of intracellular aspartate metabolism, malate, which is not detectable in the blood, as a surrogate for intracellular asparaginase activity.
Statistics and reproducibility.
Data are presented as the mean ± s.e.m. The sample size (n) indicates the experimental replicates from a single representative experiment; the results of the experiments were validated by independent repetitions. For all experiments, each data point analysed was from an independent biological sample. The experiments in Fig. 4b and Supplementary Figs. 2c, 3d and 4e were repeated once. Statistical significance was typically determined using an unpaired, one-tailed t-test, in which significance was determined as P ≤ 0.05. Determination of the statistical significance of tumour formation efficiency was determined by a two-sided Fisher's exact test. A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
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Software and code
Policy information about availability of computer code
Data collection
No software was used to collect data.
Data analysis
Graphpad Prism 7.0 was used for statistical tests. Image Studio Lite was used to visualize Western blots that were developed using an Odyssey scanner (Licor). Mass spectrometry data was analyzed with XCalibur QuanBrowser 2.2.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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Sample size
Experiments were performed using sample sizes based on standard protocols in the field. No statistical test was performed to predetermine sample size.
Data exclusions No data was excluded.
Replication
All attempts to replicate the experiments performed here were successful.
Randomization Allocation of groups was random.
Blinding
The investigator was not blinded to group allocation, although results were qualitatively verified by blinded investigators. For the metformin xenograft experiment, quantitation of tumor volumes was done by a blinded investigator as discussed in methods.
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Antibodies
Antibodies used
Primary antibodies: FLAG (Cell Signaling, 2368, 1:1000), Vinculin (Abcam, ab18058, 1:10,000), ASNS (Sigma, HPA029318, 1:250), HIF1alpha (BD Transduction Laboratories, 610958, 1:250). Secondary antibodies: IR680LT dye conjugated anti-rabbit IgG (Licor Biosciences, 925-68021, 1:10,000), IR800 dye conjugated anti-mouse IgG (Licor Biosciences, 925-32210, 1:10,000), HRP-linked Anti-mouse IgG (Cell Signaling, 7076S, 1:10,000).
Validation
Antibodies were validated by the suppliers and by the appearance of a band at the predicted size and using biologically relevant conditions (hypoxia increasing HIF1alpha). Otherwise the antibodies were not validated before use, but are standard antibodies in the field.
